DK3122752T3 - 4'-substituerede nukleosidderivater som hiv-reverse transskriptasehæmmere - Google Patents

4'-substituerede nukleosidderivater som hiv-reverse transskriptasehæmmere Download PDF

Info

Publication number
DK3122752T3
DK3122752T3 DK15715934.4T DK15715934T DK3122752T3 DK 3122752 T3 DK3122752 T3 DK 3122752T3 DK 15715934 T DK15715934 T DK 15715934T DK 3122752 T3 DK3122752 T3 DK 3122752T3
Authority
DK
Denmark
Prior art keywords
reverse transcriptase
transcriptase inhibitors
hiv reverse
substituted nucleoside
nucleoside derivatives
Prior art date
Application number
DK15715934.4T
Other languages
English (en)
Inventor
Vinay M Girijavallabhan
David B Olsen
Zhibo Zhang
Jianmin Fu
Bing-Yu Tang
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52824598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3122752(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of DK3122752T3 publication Critical patent/DK3122752T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK15715934.4T 2014-03-28 2015-03-26 4'-substituerede nukleosidderivater som hiv-reverse transskriptasehæmmere DK3122752T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2014/074294 WO2015143712A1 (en) 2014-03-28 2014-03-28 4'-substituted nucleoside reverse transcriptase inhibitors
PCT/US2015/022621 WO2015148746A1 (en) 2014-03-28 2015-03-26 4'-substituted nucleoside-derivatives as hiv reverse transcriptase inhibitors

Publications (1)

Publication Number Publication Date
DK3122752T3 true DK3122752T3 (da) 2021-10-25

Family

ID=52824598

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15715934.4T DK3122752T3 (da) 2014-03-28 2015-03-26 4'-substituerede nukleosidderivater som hiv-reverse transskriptasehæmmere

Country Status (41)

Country Link
US (2) US9777035B2 (da)
EP (1) EP3122752B1 (da)
JP (1) JP6182680B2 (da)
KR (1) KR101961009B1 (da)
CN (1) CN106795199B (da)
AP (1) AP2016009482A0 (da)
AR (1) AR099788A1 (da)
AU (2) AU2015236018B2 (da)
CA (1) CA2943792C (da)
CL (1) CL2016002414A1 (da)
CR (1) CR20160451A (da)
CY (1) CY1124829T1 (da)
DK (1) DK3122752T3 (da)
DO (1) DOP2016000265A (da)
EA (1) EA031476B1 (da)
EC (1) ECSP16085206A (da)
ES (1) ES2894228T3 (da)
GE (1) GEP20197009B (da)
GT (1) GT201600201A (da)
HR (1) HRP20211622T1 (da)
HU (1) HUE056913T2 (da)
IL (1) IL247923B (da)
JO (1) JO3636B1 (da)
LT (1) LT3122752T (da)
MA (1) MA39809B1 (da)
MD (1) MD4812C1 (da)
MX (1) MX367058B (da)
MY (1) MY194635A (da)
NI (1) NI201600145A (da)
NZ (1) NZ724343A (da)
PE (1) PE20170197A1 (da)
PH (1) PH12016501897A1 (da)
PL (1) PL3122752T3 (da)
PT (1) PT3122752T (da)
RS (1) RS62418B1 (da)
SG (1) SG11201608031PA (da)
SI (1) SI3122752T1 (da)
SV (1) SV2016005290A (da)
TW (1) TWI660967B (da)
UA (1) UA120758C2 (da)
WO (2) WO2015143712A1 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41213A (fr) * 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
UA123701C2 (uk) 2015-08-13 2021-05-19 Мерк Шарп І Доум Корп. Циклічні динуклеотидні сполуки як агоністи sting
CA2998646C (en) * 2015-09-23 2021-05-18 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors and preparations thereof
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
WO2017223414A1 (en) 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
BR112019006816A8 (pt) 2016-10-04 2023-02-07 Merck Sharp & Dohme Compostos de benzo[b]tiofeno como agonistas de sting, composição farmacêutica e uso dos mesmos
JP7125714B2 (ja) * 2016-12-13 2022-08-25 ヤマサ醤油株式会社 抗ウイルス活性を有する２’－デオキシ－７－デアザプリンヌクレオシド誘導体
US11466047B2 (en) 2017-05-12 2022-10-11 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
AU2018311966A1 (en) 2017-08-04 2020-02-13 Merck Sharp & Dohme Llc Benzo[b]thiophene sting agonists for cancer treatment
JP2020529421A (ja) 2017-08-04 2020-10-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． がんの処置のためのＰＤ−１アンタゴニストおよびベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニストの組み合わせ
SG11202002295QA (en) * 2017-09-18 2020-04-29 Janssen Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
WO2019125974A1 (en) 2017-12-20 2019-06-27 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
MX2020006864A (es) * 2017-12-27 2020-11-11 Univ Emory Modalidades combinadas para inhibidores de nucleosidos y/o nadph oxidasa (nox) como agentes antivirales especificos de mieloides.
US20200407393A1 (en) * 2018-03-07 2020-12-31 Glaxosmithkline Intellectual Property (No. 2) Limited Medical Use
CA3095646A1 (en) 2018-04-03 2019-10-10 Merck Sharp & Dohme Corp. Benzothiophenes and related compounds as sting agonists
WO2019195063A1 (en) 2018-04-03 2019-10-10 Merck Sharp & Dohme Corp. Aza-benzothiophene compounds as sting agonists
EP3820473A4 (en) * 2018-07-09 2022-05-11 Merck Sharp & Dohme Corp. ENZYMATIC SYNTHESIS OF 4'-ETHINYL NUCLEOSIDE ANALOGUES
US20220117993A1 (en) * 2018-08-09 2022-04-21 Glaxosmithkline Intellectual Property (No. 2) Limited Compounds Useful in HIV Therapy
UA128041C2 (uk) 2019-01-25 2024-03-20 Браун Юніверсіті Спосіб лікування пов'язаного з віком запалення у пацієнта
WO2020178767A1 (en) * 2019-03-06 2020-09-10 Glaxosmithkline Intellectual Property Development Limited Compounds useful in hiv therapy
CN110054654B (zh) * 2019-05-27 2022-12-27 武汉百科药物开发有限公司 一种地西他滨中间体α-取代脱氧核糖的合成方法
CA3150467A1 (en) * 2019-09-11 2021-03-18 Arnab Kumar CHATTERJEE ANTIVIRAL PRODRUGS AND FORMULATIONS THEREOF
TW202135815A (zh) * 2019-12-09 2021-10-01 美商 Ｖｉｉｖ 醫療保健公司 醫藥組合物
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
CN112321589B (zh) * 2020-02-18 2022-05-03 山东科巢生物制药有限公司 一种抗病毒药物瑞德西韦及其中间体的合成方法
AU2021237718B2 (en) 2020-03-20 2023-09-21 Gilead Sciences, Inc. Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
CN112778310A (zh) * 2020-04-20 2021-05-11 中国科学院上海药物研究所 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
CN113527303B (zh) * 2020-04-21 2022-06-10 浙江工业大学 一种瑞德西韦母核中间体的制备工艺
CN113637041B (zh) * 2020-05-11 2024-02-27 上海科胜药物研发有限公司 一种核糖核苷的制备方法
PE20230779A1 (es) 2020-08-07 2023-05-09 Gilead Sciences Inc Profarmacos de analogos de nucleotidos de fosfonamida y su uso farmaceutico
US20240101589A1 (en) 2020-10-08 2024-03-28 Strom Therapeutics Limited Inhibitors of mettl3
CN112300236A (zh) * 2020-10-21 2021-02-02 佛山科学技术学院 核苷酸混合氨基磷酸酯化合物、其药物组合物及其应用
US11793827B2 (en) 2021-01-25 2023-10-24 Brii Biosciences, Inc. Adenosine derivative and pharmaceutical composition comprising the same
TW202237146A (zh) 2021-01-25 2022-10-01 美商布里生物科學股份有限公司 使用腺苷衍生物及衣殼抑制劑之hiv組合療法
JP2024512771A (ja) 2021-04-16 2024-03-19 ギリアード サイエンシーズ， インコーポレイテッド アミドを使用してカルバヌクレオシドを調製する方法
KR20240050362A (ko) 2021-08-20 2024-04-18 시오노기 앤드 컴파니, 리미티드 바이러스 증식 억제 작용을 갖는 뉴클레오사이드 유도체 및 그들의 프로드러그
WO2023046900A1 (en) 2021-09-23 2023-03-30 Katholieke Universiteit Leuven Ribonucleoside analogues against -sars-cov-2

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9105935A (pt) 1990-01-11 1992-11-17 Isis Pharmaceuticals Inc Composicao,analogo de oligonucleotideo,oligonucleotideo sequenciado misto,processo para a preparacao de nucleosideos 2'-substituidos,composicao para modular a atividade de rna,processos para modular a producao de uma proteina por um organismo,para tratar um animal,para detectar a presenca ou ausencia de rna,oligonucleotideo ou analogo de analogo de oligonucleotideo resistente a nuclease e processo para tratar um organismo tendo uma doenca
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
SK48199A3 (en) 1996-10-16 2000-01-18 Icn Pharmaceuticals Purine l-nucleosides, analogs and uses thereof
BR0011521B8 (pt) 1999-05-12 2021-05-25 Yamasa Corp compostos nucleósidos de purina de 4 -c-etinila
US6831069B2 (en) 1999-08-27 2004-12-14 Ribapharm Inc. Pyrrolo[2,3-d]pyrimidine nucleoside analogs
WO2003062256A1 (en) 2002-01-17 2003-07-31 Ribapharm Inc. 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents
AU2003237249A1 (en) 2002-05-24 2003-12-12 Isis Pharmaceuticals, Inc. Oligonucleotides having modified nucleoside units
US20040229839A1 (en) 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
WO2005003047A1 (en) 2003-07-03 2005-01-13 Philips Intellectual Property & Standards Gmbh Pane which can be heated by means of invisible light
CA2502109C (en) 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
CA2637879A1 (en) 2006-02-14 2007-08-23 Merck & Co., Inc. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
CN101003550B (zh) * 2006-12-30 2010-05-19 河南省分析测试研究中心 8-卤代腺嘌呤类核苷化合物、合成方法和其药物用途
JP2010515760A (ja) 2007-01-12 2010-05-13 バイオクライスト ファーマシューティカルズ， インコーポレイテッド 抗ウイルス性ヌクレオシド類似体
CN100532388C (zh) * 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
US20090318380A1 (en) * 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
TW201334784A (zh) 2008-04-23 2013-09-01 Gilead Sciences Inc 抗病毒性治療用的１’－經取代碳－核苷類似物
WO2010036407A2 (en) 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
EP2313102A2 (en) 2008-07-03 2011-04-27 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
GB0815968D0 (en) 2008-09-03 2008-10-08 Angeletti P Ist Richerche Bio Antiviral agents
EP2332953A1 (en) 2008-09-05 2011-06-15 Kotobuki Pharmaceutical Co., Ltd. Substituted amine derivative and medicinal composition comprising same as the active ingredient
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
AU2009329867B2 (en) 2008-12-23 2015-01-29 Gilead Pharmasset Llc Nucleoside phosphoramidates
DE102009000180A1 (de) 2009-01-13 2010-07-15 Evonik Degussa Gmbh Verfahren zur Herstellung von mehrschichtig beschichteten Gummipartikeln und mehrschichtig beschichtete Gummipartikel
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
JP2012521359A (ja) 2009-03-20 2012-09-13 アリオス バイオファーマ インク． 置換されたヌクレオシドアナログおよびヌクレオチドアナログ
WO2011005860A2 (en) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. 5' phosphate mimics
SG181803A1 (en) 2009-12-17 2012-07-30 Merck Sharp & Dohme Aminopyrimidines as syk inhibitors
KR20130083389A (ko) 2010-05-28 2013-07-22 바이오크리스트파마슈티컬즈,인코포레이티드 야누스 키나아제 억제제로서 헤테로사이클릭 화합물
UA111163C2 (uk) 2010-07-22 2016-04-11 Гайлід Сайєнсіз, Інк. Способи й сполуки для лікування вірусних інфекцій paramyxoviridae
TW201305185A (zh) 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之２’－氟取代之碳－核苷類似物
CA2866381C (en) 2012-03-13 2020-03-24 Gilead Sciences, Inc. 2'- substituted carba-nucleoside analogs for antiviral treatment
UA119050C2 (uk) * 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ

Also Published As

Publication number Publication date
JO3636B1 (ar) 2020-08-27
WO2015143712A1 (en) 2015-10-01
JP6182680B2 (ja) 2017-08-16
SG11201608031PA (en) 2016-10-28
GEP20197009B (en) 2019-08-12
DOP2016000265A (es) 2017-04-30
RS62418B1 (sr) 2021-10-29
AP2016009482A0 (en) 2016-10-31
TWI660967B (zh) 2019-06-01
MA39809B1 (fr) 2021-10-29
PH12016501897A1 (en) 2016-12-19
CA2943792C (en) 2020-02-25
BR112016022438A8 (pt) 2021-06-29
UA120758C2 (uk) 2020-02-10
EP3122752A1 (en) 2017-02-01
HRP20211622T1 (hr) 2022-03-04
CN106795199B (zh) 2020-01-10
ES2894228T3 (es) 2022-02-14
IL247923B (en) 2021-01-31
LT3122752T (lt) 2021-11-10
EA201691931A1 (ru) 2017-02-28
CN106795199A (zh) 2017-05-31
SV2016005290A (es) 2018-05-03
PL3122752T3 (pl) 2022-01-03
NI201600145A (es) 2016-10-27
CY1124829T1 (el) 2022-11-25
AU2017225090A1 (en) 2017-09-28
PE20170197A1 (es) 2017-03-22
MD20160117A2 (ro) 2017-02-28
HUE056913T2 (hu) 2022-03-28
EP3122752B1 (en) 2021-08-25
CR20160451A (es) 2016-12-06
BR112016022438A2 (pt) 2017-08-15
AR099788A1 (es) 2016-08-17
PT3122752T (pt) 2021-10-20
ECSP16085206A (es) 2017-08-31
AU2015236018B2 (en) 2017-09-28
US20180002366A1 (en) 2018-01-04
MY194635A (en) 2022-12-08
CL2016002414A1 (es) 2017-05-05
MX367058B (es) 2019-08-02
US9777035B2 (en) 2017-10-03
MD4812C1 (ro) 2023-01-31
MA39809A (fr) 2021-04-07
AU2017225090B2 (en) 2018-08-09
AU2015236018A1 (en) 2016-10-06
US20150274767A1 (en) 2015-10-01
NZ724343A (en) 2020-02-28
CA2943792A1 (en) 2015-10-01
TW201619180A (zh) 2016-06-01
KR101961009B1 (ko) 2019-03-21
IL247923A0 (en) 2016-11-30
JP2017512797A (ja) 2017-05-25
GT201600201A (es) 2018-12-18
WO2015148746A1 (en) 2015-10-01
KR20160128437A (ko) 2016-11-07
MD4812B1 (ro) 2022-06-30
SI3122752T1 (sl) 2021-11-30
MX2016012659A (es) 2016-12-14
EA031476B1 (ru) 2019-01-31

Similar Documents

Publication Publication Date Title
DK3122752T3 (da) 4'-substituerede nukleosidderivater som hiv-reverse transskriptasehæmmere
DK3464249T3 (da) Substituerede carbonnukleosidderivater, der er anvendelige som anticancermidler
DK3464271T3 (da) Pyrazolderivater som plasma-kallikreininhibitorer
IL253637A0 (en) History of mutated nucleosides useful as anticancer agents
DK3302448T3 (da) Erstattede heterocyclylafledninger som cdk-inhibitore
DK3464309T3 (da) Phosphoramidatnukleosidderivater som anticancermidler
DK3204381T3 (da) N-pyridinylacetamidderivater som wnt-signaleringsbanehæmmere
DK3149001T3 (da) Hidtil ukendte pyrazolopyrimidinderivater og deres anvendelse som MALT1-hæmmere
DK3119762T3 (da) Benzimidazol-derivater som erbb-tyrosin-kinase-inhibitorer til behandlingen af kræft
DK3313832T3 (da) 3-tetrazolyl-benzen-1,2-disulfonamidderivater som metallo-beta- lactamase-hæmmere
DK3094631T3 (da) Pyrimidinyloxybenzenderivater som herbicider
HK1225617A1 (zh) 作為流感rna複製的抑制劑的4’-二氟甲基取代的核苷衍生物
DK3601225T3 (da) Substituerede indolinderivater som inhibitorer af denguevirus-replikation
DK3204378T6 (da) N-pyridinylacetamidderivater som hæmmere af wnt-signaleringsbanen
CL2018001672A1 (es) Formulaciones para derivados de fosforamidato de farmacos nucleosidos.
DK3153508T3 (da) Naphthofuranderivater til anvendelse som anticancermidler
DK3256483T3 (da) Hidtil ukendt c-3-triterpenon med omvendte c-17-amidderivater som hiv-hæmmere patentkrav
LT3125894T (lt) Živ atvirkštinės transkriptazės inhibitorių provaistai
DK3766885T3 (da) Tricykliske forbindelser og deres anvendelse som phoshodiesteraseinhibitorer
DK3355933T3 (da) Adeninkonjugatforbindelser og deres anvendelse som vaccineadjuvanser
DK3277682T3 (da) 6-morpholinyl-2-pyrazolyl-9h-purinderivater og anvendelse heraf som pi3k- hæmmere
DK3196194T3 (da) Pyrimidinderivater, der er nyttige som selektive jak3- og/eller jak1-inhibitorer
DK3372589T3 (da) Pyrimidinderivat
DK3319970T3 (da) Pyrido-oxazinonderivater som tnap-hæmmere
DK3233839T3 (da) Heterocyclylkoblede imidazopyridazinderivater som pi3k-beta-inhibitorer